节点文献
地西泮合并心理干预治疗酒依赖伴抑郁35例疗效评价
Diazepam Combined with Psychological Intervention for Treating Alcohol Dependence Complicating Depression in 35 Cases
【摘要】 目的观察地西泮合并心理干预治疗酒依赖伴抑郁的疗效。方法随机将70例患者分成地西泮合并心理干预治疗组(干预组)和单用地西泮治疗组(对照组),各35例,均治疗8周。于治疗前及治疗后采用汉密尔顿抑郁量表(HAMD)、汉密尔顿焦虑量表(HAMA)、临床总体印象量表(CGI)评定临床疗效及不良反应。结果治疗后第1,2,4,8周末的HAMD,HAMA及CGI评分,干预组和对照组均显著低于治疗前(P<0.05),且干预组各时间点的评分均显著低于对照组(P<0.05);干预组总有效率为94.29%,显著高于对照组的74.29%(P<0.05);干预组不良反应发生率为25.71%,显著低于对照组的60.00%(P<0.05)。结论地西泮合并心理干预治疗酒依赖伴抑郁的疗效优于单用地西泮,且起效更快,不良反应少。
【Abstract】 Objective To observe the clinical efficacy of diazepam combined with psychological intervention in the treatment of alcohol dependence complicating depression.Methods 70 patients with alcohol dependence complicating depression were randomly assigned to the intervention group treated by diazepam combined with the psychological intervention(intervention group) and single diazepam treatment group(control group),35 cases in each group.The treatment lasted for 8 weeks.The curative effects and adverse reactions were assessed before treatment and at the end of 1,2,4,8 weeks by adopting the Hamilton depression scale(HAMD),Hamilton anxiety scale(HAMA),clinical general impression(CGI) and treatment emergent symptom scale(TESS).Results The scores of HAMD,HAMA and CGI after 1,2,4,8 weeks of treatment in both groups were significantly lower than before treatment(P < 0.05),moreover which at various time points in the intervention group were significantly lower than those in the control group(P < 0.05) The effective rate in the intervention group was 94.29%,which was significantly higher than 74.29% in the control group(P < 0.05);the incidence rate of adverse reactions in the intervention group was 25.71%,which was significantly lower than 60.00% in the control group,the difference was statistically significant(P < 0.05).Conclusion Diazepam combined with psychological intervention has better effect with rapid onset and less adverse reactions for treating alcohol dependent complicating depression than single use of diazepam.
- 【文献出处】 中国药业 ,China Pharmaceuticals , 编辑部邮箱 ,2015年13期
- 【分类号】R749.62
- 【被引频次】4
- 【下载频次】67